CURANEX PHARMACEUTICALS INC (CURX) Stock Price, Forecast & Analysis
NASDAQ:CURX • US23126K1060
CURX Key Statistics, Chart & Performance
The current stock price of CURX is 0.2815 USD. In the past month the price decreased by -20.81%.
CURX Technical Analysis
CURX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CURX. CURX has a great financial health rating, but its profitability evaluates not so good.
CURX Financial Highlights
Over the last trailing twelve months CURX reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS decreased by -1757.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.45% | ||
| ROE | -10.59% | ||
| Debt/Equity | 0 |
CURX Forecast & Estimates
CURX Ownership
CURX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.21 | 959.759B | ||
| JNJ | JOHNSON & JOHNSON | 21.09 | 580.304B | ||
| MRK | MERCK & CO. INC. | 22.2 | 296.13B | ||
| PFE | PFIZER INC | 9.23 | 157.665B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.88 | 122.002B | ||
| ZTS | ZOETIS INC | 18.39 | 56.704B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.65 | 25.543B | ||
| VTRS | VIATRIS INC | 6.28 | 18.578B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.76 | 12.774B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.19 | 9.387B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CURX
Company Profile
Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Company Info
CURANEX PHARMACEUTICALS INC
2 Jericho Plaza, Suite101B
Jericho NEW YORK US
Employees: 0
Phone: 17186736078
CURANEX PHARMACEUTICALS INC / CURX FAQ
What does CURANEX PHARMACEUTICALS INC do?
Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
What is the stock price of CURANEX PHARMACEUTICALS INC today?
The current stock price of CURX is 0.2815 USD. The price decreased by -0.57% in the last trading session.
Does CURANEX PHARMACEUTICALS INC pay dividends?
CURX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CURX stock?
CURX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CURANEX PHARMACEUTICALS INC (CURX)?
CURANEX PHARMACEUTICALS INC (CURX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
Would investing in CURANEX PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CURX.